Pancreatic Cancer Research

ResearcherChina Pharmaceutical UniversityActive in the last 2 years

Shu-Ping Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0086-260X; OpenAlex author ID A5009086064. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

  1. FOS-Like Antigen 1 Regulates Proliferating Cell Nuclear Antigen Expression and Pancreatic Cancer Cell Proliferation and Migration. Last author DOI 10.31083/fbl52523↗
  2. Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer. Co-author DOI 10.1021/acs.jmedchem.1c01535↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xueyan Zhang · 1 shared paper, 2026 · strength 0.36
  2. Yungen Xu · 1 shared paper, 2021 · strength 0.12
  3. Yu Li · 1 shared paper, 2021 · strength 0.12
  4. Qin Sun · 1 shared paper, 2021 · strength 0.12
  5. Shihui Huang · 1 shared paper, 2021 · strength 0.12
  6. Shiqi Wu · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.